Verfahren zur Herstellung von Dibenzocycloheptenverbindungen

Novel compounds of the general formula <FORM:1061946/C2/1> wherein R and R1 each stand for a halogen atom or a trifluoromethyl, alkyl, alkoxy, alkylthio, acyl, sulphamyl, or alkylsulphamyl group, Ra stands for a hydrogen atom or an alkyl group (which may be substituted by alkoxy, amino or phen...

Full description

Saved in:
Bibliographic Details
Main Authors HANS SPIEGELBERG,DR, EMILIO KYBURZ,DR
Format Patent
LanguageGerman
Published 25.09.1969
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Novel compounds of the general formula <FORM:1061946/C2/1> wherein R and R1 each stand for a halogen atom or a trifluoromethyl, alkyl, alkoxy, alkylthio, acyl, sulphamyl, or alkylsulphamyl group, Ra stands for a hydrogen atom or an alkyl group (which may be substituted by alkoxy, amino or phenyl groups) and Rb stands for a hydrogen atom, a cycloalkyl group, an alkyl group (which may be substituted by alkoxy, amino, or phenyl groups) or an acyl group or Ra and Rb together with the nitrogen atom to which they are attached form a five-membered or six-membered heterocyclic ring which may be alkyl-substituted and wherein the broken lines denote that the substituents attached thereby are optional, and acid addition salts thereof are obtained by reacting a compound of the general formula <FORM:1061946/C2/2> wherein R, R1 and the broken lines have the above significance and X stands for a halogen atom or for a hydroxy group which is esterified with a sulphonic acid, with an amine of the formula <FORM:1061946/C2/3> wherein Ra and Rb have the above significance if desired, introducing Ra and/or Rb groups differing from hydrogen by alkylation, cyclo-alkylation, aralkylation, acylation or acylation and reduction, if desired converting any alkoxy-alkyl group present into an amino-alkyl group by halogenation and reaction with an appropriate amine and, also if desired, converting the product into an acid addition salt. Pharmaceutical compositions having reserpine-antagonism and central stimulant activity containing the above compounds are administered enterally, percutaneously or parenterally.
Bibliography:Application Number: DE19651543035